Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 158

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 18
Chunk 158
---
) examines internal reports to assess the Group’s performance and determine the allocation of resources. The Group has identified one reportable segment as a whole and this covers research into Parkinsonian movement disorders, Alzheimer’s disease, Huntington disease, and other neurodegenerative disorders.

 

23. FINANCIAL INSTRUMENTS
 
The Group’s activities expose it to a variety of financial risks including market risk, credit risk and liquidity risk. The Group’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the financial performance of the Group. Risk management is carried out under policies approved by the Board of Directors and overseen by the Audit Committee.   
(a)   Market Risk
-----------------

(i)   Foreign Currency Risk
---------------------------
   The Group engages in international purchase transactions and is exposed to foreign currency risk arising from various currency exposures, primarily with respect to the Australian dollar. The parent entity also has exposure to foreign exchange risk in the currency cash reserves it holds to meet its foreign currency payments. The Group does not make use of derivative financial instruments to hedge foreign exchange risk.   The following financial assets and liabilities are subject to foreign currency risk, the currency of the original amounts are displayed in brackets, all the amounts in the table below are displayed in A$ at year-end spot rates:   
                                                  Consolidated Entity                 
--------------------------------------------------------------------------------------
                                  2025                        2024                    
                                      A$                            A$                
Cash and cash equivalents (USD)             1,544,448                      225,722    
Trade and other payables (USD)               (495,145   )                 (507,820   )
Trade and other payables (£GBP)       796                                   (3,834   )
Trade and other payables (JPY)                      -                       (2,992   )
Total exposure                              1,050,099                     (288,924   )
   As shown in the table above, the Group is primarily exposed to changes in USD/AUD exchange rates. The sensitivity of profit or loss to changes in the exchange rates arises mainly from US-dollar denominated financial instruments and there is no impact on other components of equity.   Based on the financial instruments held as of June 30, 2025, had the Australian dollar weakened/strengthened by 1.77%
 (2024: 0.35%, 2023: 3.6%) against the USD with all other variables held constant, the Group’s post-tax loss for the year would have been A